GlassScriptPhysician profile
Yevheniya Khrobust
NPI 1013528488
$12,341.21
in general payments reported to CMS, 2019-2025
38 companies · $4,276 in 2025
The $4,276 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $401 · 2024: $7,539 · 2025: $4,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $1,805 · Gift: $100 · Education: $27.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,283.70 |
| Travel and Lodging | $1,804.89 |
| Gift | $100.00 |
| Education | $27.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,493.46 | 2024-2025 | Vns Therapy |
| Ucb, INC. | $2,058.18 | 2023-2025 | Briviact, Fintepla, Zilbrysq |
| Abbvie INC. | $1,404.09 | 2024-2025 | |
| Sk Life Science, INC. | $1,149.57 | 2023-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $589.05 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lilly USA, LLC | $496.19 | 2023-2025 | Kisunla, Reyvow, Emgality |
| Pfizer INC. | $450.28 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $332.03 | 2024-2025 | |
| Biogen, INC. | $294.18 | 2024-2025 | Vumerity, Tysabri |
| Neurocrine Biosciences, INC. | $278.51 | 2023-2025 | Ingrezza |
| Scilex Pharmaceuticals INC. | $266.35 | 2023-2025 | Ztlido |
| Lundbeck LLC | $262.86 | 2023-2025 | Vyepti |
| Eisai INC. | $261.63 | 2023-2025 | |
| Neurelis, INC. | $199.16 | 2024-2025 | Valtoco |
| Averitas Pharma INC. | $145.05 | 2024 | Qutenza |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $144.47 | 2024-2025 | |
| Argenx US, INC. | $142.96 | 2024-2025 | Vyvgart Hytrulo |
| Janssen Scientific Affairs, LLC | $124.64 | 2022 | |
| Axsome Therapeutics, INC. | $121.36 | 2025 | Symbravo |
| Alnylam Pharmaceuticals INC. | $119.67 | 2024-2025 | Amvuttra |
| Novo Nordisk INC | $118.97 | 2025 | Wegovy |
| Incyte Corporation | $115.64 | 2024 | Opzelura |
| J2 Bio-Pharma LLC | $100.00 | 2024 | |
| Csl Behring | $86.77 | 2025 | Hizentra, Kcentra |
| Alexion Pharmaceuticals, INC. | $83.98 | 2024 | Ultomiris |
| Merz Pharmaceuticals, LLC | $71.85 | 2024-2025 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $59.08 | 2024-2025 | Dysport |
| Grifols USA, LLC | $54.49 | 2024-2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $46.84 | 2024-2025 | Radicava |
| Amneal Pharmaceuticals LLC | $44.35 | 2024 | Rytary |
| Banner Life Sciences, LLC | $43.42 | 2024 | |
| Impel Pharmaceuticals LLC | $41.80 | 2024-2025 | Trudhesa |
| Acadia Pharmaceuticals INC | $25.51 | 2024 | Nuplazid |
| Amgen INC. | $24.71 | 2024 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $24.67 | 2024 | |
| Tg Therapeutics, INC. | $23.23 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $21.29 | 2025 | Wainua |
| Emd Serono, INC. | $20.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevheniya Khrobust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.